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MR mammographyAbstract Introduction: The purpose of this study is to detect the diagnostic accuracy of
dual-energy contrast-enhanced digital mammography (CEDM) in the diagnosis of breast cancer.
Methods: Twenty-one females with pathologically proven breast cancer underwent CEDM, prior
to their scheduled surgeries. BI-RADS scores were evaluated for all lesions. Written consent was
obtained from all patients prior to the studies.
Results: Contrast-enhanced digital mammography (CEDM) showed focal enhancement in 19
patients. The kinetic curves of enhancement were classiﬁed as type 2 in 13 patients and type 3 in
six patients. For the two false negative cases, no enhancement was noted on CEDM.
Conclusions: Dual-energy contrast-enhanced digital mammography improves the diagnostic
accuracy of full ﬁeld digital mammography in the detection of breast cancer.
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Full-ﬁeld digital mammography (FFDM) enables high-quality
breast images with higher-contrast resolution, improved dy-
namic range, and rapid processing of data and images com-
RE pared with conventional mammography. FFDM has beenshown to provide increased accuracy in screening pre- orperi-menopausal women, women younger than 50, and womenwith dense breasts. Moreover, FFDM offers the possibility of
developing new and advanced applications for breast imaging.
Contrast-enhanced digital mammography (CEDM) with injec-
tion of an iodinated contrast agent is one of them (1).
During the past few years, many methods for imaging angi-
ogenesis in vivo have been developed. Digital subtraction angi-
ography of the breast has been performed using a radiograph
image intensiﬁer system (2,3). Subtracted images of malignant
tumors showed rapid and strong enhancement followed by a
washout, whereas benign tumors showed less or no enhance-
ment. At present, contrast medium is used with both CT and
MRI techniques to explore angiogenesis in breast carcinoma.
Fig. 1 Schematic drawing of the time-signal intensity curve
types.
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AIodinated contrast-enhanced conventional CT was shown to
be useful for detecting breast carcinoma. However, conven-
tional CT results in a high-radiation dose to the breast and
chest wall. Recent studies on dedicated breast CT with radia-
tion doses similar to or slightly higher than those of two-view
mammography have shown that malignant lesions were signif-
icantly more conspicuous at contrast-enhanced breast CT than
at mammography (4,5). Breast MRI using gadolinium-based
contrast agents is currently considered the most sensitive imag-
ing technique for the detection of breast carcinoma, and multi-
ple indications have been established for breast MRI (6).
However, breast MRI has a variable speciﬁcity and positive
predictive value and is more time-consuming and more
expensive than mammography (7,8).
Investigational clinical results on CEDM have been
published during the last few years, suggesting that the tech-
nique may be a useful adjunct to FFDM with lesion contrast
uptake information (9,10). Two CEDM examination tech-
niques have been investigated: temporal subtraction and
dual-energy. The study by Lewin and colleagues (9) is the only
published preliminary clinical experience using dual-energy
CEDM. The authors showed the technical and clinical feasibil-
ities of this technique and reported a high sensitivity and
speciﬁcity for the detection of breast carcinoma.
2. Materials and methods
2.1. Patients
From August 2011 to May 2013, twenty-one females with
pathologically proven breast cancer were included in the study.
All patients provided written informed consents for perfor-
mance of FFDM and CEDM. The study was approved by
the ethics committee and the institutional review board. Exclu-
sion criteria were pregnancy or possible pregnancy, or a
history of allergic reaction to an iodinated contrast agent.
The patients had a mean age ± standard deviation (SD) of
53 ± 9 years. Suspicious breast lesions included palpable
masses in six patients, mammographic opacities in eleven pa-
tients (eight with spiculated masses and three with asymmetri-
cal breast densities), and sonographic masses in thirteen
patients. Breast densities were classiﬁed as BI-RADS category
2 in nine patients, and category 3 in twelve patients.
The masses were pathologically proven as breast cancer by
histopathological analysis of the excised specimens.
2.2. Dual-energy CEDM examinations
All CEDM examinations were performed within 7 days before
breast surgery with a digital mammography machine (Selenia,
Hologic Dimensions, Bedford, USA) which allowed dual-en-
ergy CEDM acquisitions. Dual-energy CEDM was performed
by acquiring a pair of low- and high-energy images in quick
succession during a single breast compression.
Patients were comfortably settled to avoid motion. A
catheter was inserted into the antecubital vein of the arm con-
tra lateral to the breast of concern. Light breast compression
was used for all images, which was strong enough to limit
motion, but not to reduce blood ﬂow. A single mask mammo-
gram was ﬁrst taken. A single shot of 1.5 mL/body weight of
non-ionic contrast medium (Iohexol (Omnipaque) 300; GE
RE
TRhealthcare, USA) was given using a power injector (Vistron
CT, Medrad), at a rate of 3 mL/s The ﬁrst contrast-enhanced
mammogram was obtained 30 s after starting the injection,
and subsequent mammograms were obtained after 90, 150,
240, 330, and 420 s. Therefore, a total of seven mammograms
including six contrast-enhanced mammograms were obtained
for each patient. The total X-ray dose delivered to the patient
depended on breast thickness and tissue composition.
The mean examination duration was approximately 15 min
(ranging from 12 to 25 min). The maximum total radiograph
dose of the procedure ranged between 1 and 4 mGy, which is
similar to a conventional single-view mammogram.
2.3. Image analysis
The displayed images show the regions of contrast uptake
while canceling non-enhancing anatomic noise in the back-
ground. Image processing included a logarithmic subtraction
and the analysis of enhancement kinetic curves. The maximum
diameter of the tumor measured on subtracted contrast-en-
hanced digital mammography images was recorded. Regions
of interest were placed at areas of early enhancement and adja-
cent breast tissues to analyze the uptake and the washout of
the contrast agent. To minimize the effect of breast thickness
on density values, the region of interest for the lesion and
the healthy breast tissue had the same size and were located
at the same distance from the posterior aspect of the breast.
Values of differential contrast enhancement between lesions
and healthy breast tissues were then plotted versus time. The
time–intensity curves were classiﬁed into three types based
on the wash-in and washout of contrast medium: type 1,
gradually increasing enhancement, type 2, early enhancement
followed by plateau and type 3, early enhancement followed
by washout (Fig. 1). The enhancement was considered early
if the peak of enhancement was before 1 min 30 s.
For FFDM examination, the two CC and MLO images
were reviewed without any additional views.
2.4. Statistical analysis methods
Comparisons of sensitivity and speciﬁcity of FFDM and
CEDM were done using McNemar’s chi-squared test, and
comparison of false-positive and false-negative marks per case
used the Wilcoxon signed rank test. Statistical tests were per-
formed at a signiﬁcance level of 0.05.
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Fig. 2 Invasive ductal carcinoma in a 53-year old female. (A)
CEDM, mediolateral image depicts an irregular, poorly deﬁned,
mass in the lower quadrant of the breast (arrows). (B) The left
mediolateral oblique view mammogram shows a dense breast with
no deﬁnite abnormalities.
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Results for the patients are summarized in Table 1. Contrast-
enhanced digital mammography (CEDM) showed focal
enhancement in 19 patients. The median maximum diameter
of the lesions measured on the subtracted image at 90 s after
injection was 10 mm, ranging from 6 to 20 mm. The kinetic
curves of enhancement were classiﬁed as type 2 in 13 patients
and type 3 in six patients.
Morphologically, in three of the malignancies, a rim-like
appearance was observed on CEDM. Inhomogeneous
enhancement with spiculated outline was seen in two cases
(Fig. 2) and regional enhancement with no mass in one case
(Fig. 3). The other malignancies presented as irregular and
poorly deﬁned masses (Fig. 4). For the two false negative
cases, no enhancement was noted on CEDM.
Histolopathological analysis of surgical specimens is sum-
marized in Table 1. It shows malignant tumors in all patients,
including 13 invasive ductal carcinomas (IDC), three invasive
lobular carcinoma (ILC), and ﬁve ductal carcinoma in situ
(DCIS) with micro invasion, including the two false negative
cases. The median maximum diameter of lesions measured at
histology was 13 mm (range, 4–28 mm).
The comparison between contrast-enhanced digital mam-
mography and histopathological results showed 19 true-posi-
tives and two false-negatives for contrast-enhanced digital
mammography. Consequently, the sensitivity of CEDM for
detecting breast carcinomas was 90%. A good correlation was
found between the size of lesions measured on contrast-
enhanced digital mammography images and those measured
on histological sections, with a coefﬁcient of correlation of
93%.A B
Fig. 3 Invasive lobular carcinoma in a 61-year old female. (A)
The left mediolateral oblique mammogram shows no obvious
lesion in the breast. (B) CEDM, mediolateral oblique image
clearly depicts non-mass regional enhancement in the inferior
quadrant (arrowheads).
Table 1 Radiological ﬁndings in the patient population.
Clinically palpable 6






ACR 1 and 2 9
Ultrasound Detected Mass 13


















Fig. 4 Invasive ductal carcinoma in a 52-year old female. (A)
The right mediolateral mammogram shows asymmetrical density
in the upper quadrant. (B) CEDM, mediolateral image shows a
mass with spiculated enhancement (arrow and arrowheads).
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A4. Discussion
Contrast-enhanced digital mammography (CEDM) is a new
breast imaging technique that aims at demonstrating breast
carcinoma angiogenesis. Encouraging results have been
published during the last few years on CEDM as an adjunct
to mammography (11–12).
Enhanced CEDM is similar in concept to enhanced breast
MR imaging and could potentially be applicable in situations
in which MR imaging is currently used. Such situations include
detection of a primary breast cancer in a woman with a posi-
tive axillary lymph node and determination of the extent of
disease in cases of known cancer, as well as problem solving
in cases of mammographic ﬁndings that were not depicted in
US scans (9).
Some of the limitations of contrast-enhanced digital
mammography in breast imaging compared with MRI are
irradiation of the breast, lower contrast resolution, and the
use of iodinated contrast material. However, the technique is
weakly irradiating, easily implemented, inexpensive, fast, and
practical (13).
The use of iodinated contrast agents, however, is not
completely devoid of risk. Most adverse side effects are minor
and have decreased considerably with the use of low-
osmolality contrast media. Still, life-threatening reactions,
though rare, can occur in the absence of any speciﬁc risk
factors and with any type of contrast media. All personnel
(nurses, technologists, and radiologists) who administer con-
trast media must be fully prepared to treat even the most
RE
TRsevere reactions, and adequate equipment and supplies must
be available in the mammography suite (13).
Enhancement kinetics, also used for differentiating benign
from malignant lesions at MR imaging, can be determined at
CEDM with serial imaging (14). Because whole-breast images
can be acquired more rapidly than with most MR imaging
sequences, kinetic information could be determined with
greater precision (9). In this study, the mentioned enhancement
curves were used for the diagnosis of breast malignancy with
CEDM.
Using a temporal CEDM technique, both benign and
malignant breast tumors have shown progressive enhancement
with poor capability of differentiation between them. Unlike
the temporal subtraction technique, dual-energy CEDM en-
ables differential diagnosis of benign and malignant breast tu-
mors based on differences in tumor kinetics. It also has the
potential of performing bilateral examinations with only one
contrast agent injection and allows shorter acquisition dura-
tion than temporal subtraction techniques and does not re-
quire extended breast compression. This could result in
better acceptance from patients and fewer technical problems
(10). In this study, all CEDM examinations were performed
by using the dual-energy technique.
Dromain et al. (10) in their study chose the craniocaudal
projection rather than the mediolateral oblique projection to
minimize motion artifacts. However, they reported that the
craniocaudal position was questionable because it did not al-
low much breast tissues to be visualized as does the mediolat-
eral oblique view and recommended that in the future, the
protocol of contrast-enhanced digital mammography would
include craniocaudal projections with the introduction of an
additional mediolateral oblique view at the end of the exami-
nation (one image acquisition at 5 min). Lewin et al. (9) in
their study on CEDM performed the study in mediolateral ob-
lique view, which was what we did for all our patients for bet-
ter coverage of the breast tissue. We did not have problems
with motion artifacts.
Contrast-enhanced digital mammography results reported
in this study were independent of the histological type of
carcinoma, which was supported by (14) who suggested that
the rate of contrast medium enhancement is not related to
the histological type of the tumor and that enhancement is
related not only to the number of vessels, but also to functional
parameters such as vessel permeability, particularly when
using a contrast agent that is migrating to the extra cellular
ﬂuid space.
A typical contrast MRI curve for malignancy (15,16) with
rapid enhancement followed by a decrease during the delayed
phase was observed in only six of the 21 malignant lesions of
this study. These differences between kinetic curves observed
using dynamic contrast-enhanced digital mammography and
MRI are probably because of the breast compression, even
low breast compression, which may alter blood ﬂow, according
to Lewin et al. (13).
Histolopathological analysis of the two tumors with no
enhancement on CEDM of our study (false negative for malig-
nancy) showed no tumoral necrosis. Both cases had ductal car-
cinoma in situ with micro invasion, seen on digital
mammography as suspicious clustered micro calciﬁcation.
The sensitivity of CEDM for detecting breast carcinomas
was 90% in our study, which matched the results of Lewin
et al. (9) and Dromain et al. (10) who mentioned that the
CT
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respectively.
The results of this study suggest that dual-energy contrast-
enhanced digital mammography improves the diagnostic accu-
racy of full ﬁeld digital mammography in the detection of
breast cancer. In the near future, contrast-enhanced digital
mammography will probably have the beneﬁt of other digital
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